531 related articles for article (PubMed ID: 28489509)
1. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
2. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
3. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
[No Abstract] [Full Text] [Related]
5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
Tamura K; Hashimoto J; Tanabe Y; Kodaira M; Yonemori K; Seto T; Hirai F; Arita S; Toyokawa G; Chen L; Yamamoto H; Kawata T; Lindemann J; Esaki T
Cancer Chemother Pharmacol; 2016 Apr; 77(4):787-95. PubMed ID: 26931343
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
[TBL] [Abstract][Full Text] [Related]
8. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
JAMA Oncol; 2021 Feb; 7(2):271-278. PubMed ID: 33377972
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mutant AKT in Cancer.
Cancer Discov; 2016 Jan; 6(1):OF7. PubMed ID: 26577299
[TBL] [Abstract][Full Text] [Related]
10. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
12. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
13. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
14. AKT1(E17K) in human solid tumours.
Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
[TBL] [Abstract][Full Text] [Related]
15. AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Shrestha Bhattarai T; Shamu T; Gorelick AN; Chang MT; Chakravarty D; Gavrila EI; Donoghue MTA; Gao J; Patel S; Gao SP; Reynolds MH; Phillips SM; Soumerai T; Abida W; Hyman DM; Schram AM; Solit DB; Smyth LM; Taylor BS
Nat Commun; 2022 Apr; 13(1):2111. PubMed ID: 35440569
[TBL] [Abstract][Full Text] [Related]
16. AKT1
John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
[TBL] [Abstract][Full Text] [Related]
18. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML; Lien EC; Toker A
Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
Kim MS; Jeong EG; Yoo NJ; Lee SH
Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
